Navigation Links
Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
Date:9/24/2009

CAMBRIDGE, Mass., Sept. 24 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company announced today that it has formed a research and development collaboration with the Walter Reed Army Institute of Research (WRAIR) and the Naval Medical Research Center (NMRC), Silver Spring, MD to evaluate the Company's proprietary DEEP(TM) peptide copolymer technology for the potential development of dengue vaccines and point-of-care diagnostics.

After more than 70 years of work a safe and effective dengue virus (DENV) vaccine remains an elusive goal. Previous vaccine candidates have shown unpredictable interactions among the four DENVs often leading to unwanted reactogenicity and low seroconversion rates. Rapid, serotype-specific diagnosis of DENV infection is an equally perplexing problem. Existing tests are often confounded after secondary dengue infection due to extensive serotype cross-reactivity, and the rapid evolution of DENV strains in many regions of the world.

Peptimmune has developed a novel peptide copolymer-based technology, DEEP (Directed Expansion of Epitope Permutations), which may overcome these problems. The goal of this research and development collaboration is to evaluate the DEEP technology to potentially design DENV-specific peptide copolymers containing (1) potentially protective T-cell epitopes, (2) serotype-specific diagnostic epitopes, and (3) protective B-cell epitopes for generating immuno-prophylactic antibodies. WRAIR/NMRC investigators bring to the effort their expert knowledge of DENV. Evaluation of the diagnostics and vaccines generated in the collaboration will be performed in laboratory models at WRAIR/NMRC.

The results of this collaborative effort have the potential to provide important insights into dengue immunity and advance the development of a protective vaccine.

About DEEP

DEEP is a peptide copolymer technology that is able to target the hypervariable regions of viruses generating antigenic diversity to anticipate evolutionary changes and overcome immune-dominance, while preserving antigenic specificity by incorporating any desired B- or T-cell epitope. DEEP takes advantage of Peptimmune's know-how in the solid-phase manufacturing of complex peptide mixtures. The technology combines the epitope specificity of a fixed-sequence peptide with the randomness of a broadly immune-interactive copolymer.

About Peptimmune (www.peptimmune.com)

Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptides and peptide mixtures for use as novel vaccines, ligands for antibodies, and theranostics for autoimmune disorders.


'/>"/>
SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
2. Peptimmune Presentations at Upcoming Events
3. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
4. Peptimmune Announces First Close of Series D Private Financing
5. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
6. Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community
7. Cellworks Group and ISP Personal Care Collaborate to Demonstrate Effectiveness of Proteomics-Based Computer Modeling of Skin Biology
8. SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
9. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
10. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
11. DuPont and Arzeda Collaborate to Develop Improved Crops to Increase Productivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... -- The Allen Institute for Cell Science has released ... collection of gene edited, fluorescently tagged human induced ... with unprecedented clarity. Distributed through the Coriell Institute ... crucial first step toward visualizing the dynamic organization ... cells healthy and what goes wrong in disease. ...
(Date:11/30/2016)... DIEGO and BEIJING , ... a leading commercial provider of genomic services and solutions ... announced today that it has completed a USD $75 ... Merchants Bank Co., Ltd.,s CMB International Capital Management ( ... Innovation Investment Management Co., Ltd. ("SDIC Innovation") and Shanghai ...
(Date:11/30/2016)... 30, 2016   Merck , a leading science ... into a set of agreements with Evotec AG, whereby ... of genetic reagents such as CRISPR and shRNA libraries. ... offers an accelerated pathway to explore and identify new ... identification of new targets, a process that can be ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, ... 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients at CTAD ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):